Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group.

Autor:	Arevalo JF; Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Lasave AF; Retina and Vitreous Service, Clínica Privada de Ojos, Mar del Plata, Argentina., Wu L; Retina Service, Instituto de Cirugia Ocular, San Jose, Costa Rica., Acon D; Retina Service, Instituto de Cirugia Ocular, San Jose, Costa Rica., Farah ME; Retina Division, Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil., Gallego-Pinazo R; Department of Ophthalmology, Consorcio Hospital, General Universitario de Valencia, Valencia, Spain., Alezzandrini AA; Facultad de Medicina, OFTALMOS, Universidad de Buenos Aires, Buenos Aires, Argentina., Fortuna V; Facultad de Medicina, OFTALMOS, Universidad de Buenos Aires, Buenos Aires, Argentina., Quiroz-Mercado H; Department of Ophthalmology, University of Colorado School of Medicine, Denver, Colorado, USA., Salcedo-Villanueva G; Department of Ophthalmology, University of Colorado School of Medicine, Denver, Colorado, USA., Maia M; Retina Division, Retina Division, Department of Ophthalmology and Visual Sciences, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil., Serrano M; Retina Service, Clinica Oftalmologica Centro Caracas and the Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela., Rojas S; Retina Service, Fundación Hospital Nuestra Señora de la Luz, Mexico City, Mexico.
Jazyk:	angličtina
Zdroj:	The British journal of ophthalmology [Br J Ophthalmol] 2016 Dec; Vol. 100 (12), pp. 1605-1610. Date of Electronic Publication: 2016 Feb 24.
DOI:	10.1136/bjophthalmol-2015-307950
Abstrakt:	Background/aims: To report the long-term anatomical and functional outcomes of patients with centre-involved diabetic macular oedema (DME) treated with intravitreal bevacizumab (IVB). Methods: Retrospective case series. Patients diagnosed with centre-involved DME that were treated with at least one injection of 1.25 mg IVB and had a minimum follow-up of 60 months. Patients underwent measurement of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography and fluorescein angiography at baseline, 6-month, 12-month, 24-month, 36-month, 48-month and 60-month visits. The paired samples t test was used to compare the central macular thickness (CMT) and BCVA with baseline values. Statistical significance was indicated by p<0.05. Results: Two hundred and one consecutive patients (296 eyes) were included. The mean number of IVB injections per eye was 8.4±7.1 (range: 1-47 injections). At 5 years, the BCVA remained stable at 20/100 (logarithm of the minimum angle of resolution=0.7±0.4). Eighty-six (29%) eyes improved ≥2 lines of BCVA, 129 (43.6%) eyes remained stable and 81 (27.4%) eyes lost ≥2 lines of BCVA at 60 months. Mean CMT decreased from 403.5±142.2 μm at baseline to 313.7±117.7 μm over 5 years follow-up (p≤0.0001). Conclusions: The early visual gains due to IVB were not maintained 5 years after treatment. (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu